POWER OF INTELLIGENCE

Insight Center: Publications

IP Due Diligence in the Life Sciences: Key Considerations for 2019 (Part I)

Authors: Aparna Nemlekar and N. Nicole Stakleff

2/01/2019
IP Due Diligence in the Life Sciences: Key Considerations for 2019 (Part I)

This article was published on IPWatchdog.com on February 1, 2019. Reproduction in whole prohibited.

The success of a life science product, and thereby the company, rests heavily upon a combination of patent protection, regulatory exclusivity and product life cycle management. A company’s ability to formulate and articulate an integrated strategy is critical to obtaining investments, strategic partnerships and market success. In this two-part series, we will discuss recent judicial developments that affect life science companies’ IP strategies and also outline the four basic principles of an integrated IP strategy on which a company’s intellectual property audit and preparation for third-party diligence should focus. These are: (1) patent prosecution and strategy, (2) rights and ownership, (3) interplay of patent and regulatory exclusivity, and (4) freedom to operate and competitors. Part one will focus on patent prosecution and strategy, as well as rights and ownership.

Read Part One on IPWatchdog.com.

The material in this publication was created as of the date set forth above and is based on laws, court decisions, administrative rulings and congressional materials that existed at that time, and should not be construed as legal advice or legal opinions on specific facts. The information in this publication is not intended to create, and the transmission and receipt of it does not constitute, a lawyer-client relationship.

Data protection laws have changed, so we have revised our Privacy Policy.

CLOSE